Please add to your safe senders list.

The SITC Immune Monitor

Support SITC    Membership    Meetings    About SITC    

December 2015 – In this Issue

Global Impact | Education & Events | Membership | Publications| Careers

A Message from the President

Dear Society Members,

On behalf of the Society for Immunotherapy of Cancer (SITC), I would like to wish you a happy holiday and thank those who volunteered and dedicated their time to SITC and to the field over the past year. The success the Society experienced in 2015—including record-breaking attendance at our 30th Anniversary Annual Meeting & Associated Programs and a 32% increase in membership—would not have been possible without your tremendous efforts. You can help SITC continue on its upward trajectory by recruiting your colleagues to join the Society through the Connect-a-Colleague campaign. If each current member recruits two new members, we will reach our membership goal!

In addition to the Society’s exponential growth, advances in the cancer immunotherapy field have been unparalleled in 2015. Today, cancer patients have access to several approved immunotherapy agents, numerous clinical trials are in progress, and the field is bringing new and more effective treatment options to patients across a wide variety of cancers. We are also seeing advances in the understanding of the basic science underlying the success of tumor immunotherapy.

To build on this momentum and continue to propel the field forward, SITC is presenting several fellowship opportunities to young investigators in 2016. These fellowships include dedicated research for immunotherapy in non-small cell lung cancer (NSCLC), general patient-focused immunotherapy research, and basic or clinical research on related biomarkers. Presented by SITC’s Forward Fund, with generous support from industry partners, these named fellowships aim to cultivate the next generation of cancer immunotherapy experts and secure the future of the field.

Once again, thank you to all who contributed to the success of the Society and to the field in 2015. To those who were not able to be engaged in 2015, I encourage you to become more involved in your organization. As the field continues to evolve, as does SITC, and volunteers are at the core of all that we do.

I wish you all well this holiday season and look forward to working with you in 2016!


Howard L. Kaufman, MD, FACS
SITC President

Global Impact

Melanoma Bridge & Immunotherapy Bridge Bring Together Global Immunotherapy Community – Naples, Italy

Organized on behalf of Fondazione Melanoma Onlus under the auspices of Istituto Nazionale Tumori Fondazione "G. Pascale," Sidra Medical and Research Center, the Italian Association of Medical Oncology, and the Society for Immunotherapy of Cancer

Melanoma Bridge and the first-ever Immunotherapy Bridge brought together international stakeholders to examine approaches for the treatment of melanoma, as well as the translation of the melanoma experience across tumor types.

According to SITC member and 2014 JITC Best Basic Science Paper awardee, Stefani Spranger, PhD (University of Chicago), “the meeting drew the spotlight onto the tumor microenvironment and the importance of longitudinal biopsies.” Focal points included the identification of mechanisms resulting in the non-T cell inflamed phenotype, which is often linked with lack of response to checkpoint blockade, as well as combination therapies of checkpoint blockade or combined with agonistic engagement of co-stimulatory molecules.

“Several studies in mouse models as well as in patients have highlighted a tumor-specific dysfunctional T cell found in the tumor microenvironment,” explained Dr. Spranger. “This particular subset of T cells was found to express various inhibitor receptors but also stimulatory receptors and could be driven by c-Maf and/or EGR2. Further, combination therapies have shown synergistic effects in preclinical but also in clinical studies.”

Learn more about Melanoma Bridge and Immunotherapy Bridge here, and stay tuned for more on SITC’s global initiatives.

Education & Events

Save the Dates for SITC 2016 – November 9 - 13, 2016

Gaylord National Hotel & Convention Center • National Harbor, Maryland

Mark your calendars for SITC's 31st Annual Meeting & Associated Programs! Known as the premier destination for scientific exchange, education and networking in the cancer immunotherapy field, this is the conference you don't want to miss. Learn more.

Advances in Cancer ImmunotherapyTM is Coming to a City Near You

Presented by leading authorities in tumor immunology and cancer immunotherapy, all Advances in Cancer ImmunotherapyTM series CME/CE-certified programs provide attendees with an understanding of cancer immunotherapies, their therapeutic effectiveness, and the appropriate selection and management of patients.

Clinical oncologists, nurses, pharmacists and the entire medical team involved in treating cancer patients are encouraged to attend. Stay tuned for more information, including dates and 10 locations across the United States!

Immuno-Oncology 360º Early Registration Closes Today

February 2 - 3, 2016 • The New York Academy of Medicine • New York, New York

Presented by The Conference Forum in collaboration with the Society for Immunotherapy of Cancer

Immuno-Oncology 360° combines business and clinical development strategies with scientific updates to prepare the market for accelerating immuno-oncology clinical trials. SITC President, Howard L. Kaufman, MD, FACS (Rutgers Cancer Institute of New Jersey), will participate as a speaker and panelist alongside other leaders in the field.

Representatives from large pharma, mid-sized biopharma, biotechs and investors seeking to accelerate clinical trials in the emerging immuno-oncology space are encouraged to attend.

Learn more and get the SITC registration discount code here – but hurry, early registration closes today!

Membership Makes a Difference

Do you love being a part of SITC? Connect-a-Colleague!

New members often join SITC because a current member has invited them. Please encourage your colleagues including nurses, pharmacists and students to become official SITC members. If each SITC member recruits two others, we could quickly grow to 3,000 members!

Membership benefits include:

  • Discounted registration rates on all SITC programs
  • Eligibility to apply for SITC fellowships and grants, available exclusively to SITC members
  • Free access to SITC "Members Only" section, including meeting slides and other online resources
  • Free access to SITC's online member directory
  • Waived article processing charges (a $2,500 USD savings) for SITC’s open access journal, the Journal for ImmunoTherapy of Cancer(JITC)
  • ... and much more!

To connect a colleague, log in to your member profile here.

Publications & Resources

Journal for ImmunoTherapy of Cancer, the Resource for Cutting-Edge Science in the Field

Journal for ImmunoTherapy of Cancer (JITC) is SITC's official open access, peer-reviewed journal. It encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research to clinical application. As the global voice of the Society, JITC is the resource for SITC publications. 

Additionally, JITC features monthly technology primers produced by the SITC Immune Biomarkers Task Force. A hot topic in the field, these papers examine the latest in biomarker technologies for cancer immunotherapy. Access the articles here, and consider joining us in Bethesda, Maryland on April 1 for Immunotherapy Biomarkers 2016: Overcoming the Barriers. 

Interested in publishing in JITC? SITC members receive waived article processing charges for papers accepted through 2016. Submit your manuscript here.

Latest Career Opportunities from SITC's Job Board

Principal Scientist, Vaccine Immuno-Oncology
Pfizer, Inc. – La Jolla/San Diego, California

Postdoctoral Fellow – Laboratory of Tumor Immunology
Center for Cancer Research – Menlo Park, California

Postdoctoral Fellow, Laboratory of Brain Tumor Immunotherapy, Department of Neurological Surgery
University of California, San Francisco

Postdoctoral Fellow
AbbVie, Inc.

Group Leader, Oncology – Cancer Immunotherapy Discovery Biology
Roche Pharmaceutical Research & Early Development – Zürich

View All Job Board Listings

If you are interested in posting an open position to SITC's job board, please reference this agreement form for posting criteria or contact SITC at


Society for Immunotherapy of Cancer (SITC)
555 East Wells Street, Suite 1100 | Milwaukee, Wisconsin 53202-3823 USA
Phone: +1 414 271 2456 | Email:

© 2015 Society for Immunotherapy of Cancer

Join us on:

Twitter  LinkedIn  YouTube  Oncology Tube

If you do not wish to be included in our mailing list, please forward this message to with the word "Remove" in the subject line.

Please add to your safe senders list.